13 August 2019 - Eylea is the only anti-VEGF approved to treat four retinal conditions with a single dose strength pre-filled syringe.

Regeneron Pharmaceuticals today announced that the U.S. FDA has approved the Chemistry, Manufacturing and Controls Prior-Approval Supplement for the Eylea (aflibercept) Injection pre-filled syringe. The 2 mg, single-dose, sterilised pre-filled syringe provides physicians with a new way to administer Eylea that requires fewer preparation steps compared to vials. Market supply of the Eylea pre-filled syringe is expected to be available to physicians and patients this year.

The sterilised pre-filled syringe offers the same medicine as the currently available Eylea, in an easier to use and administer presentation.

Read Regeneron Pharmaceuticals press release